Copenhagen, 2015-12-07 13:40 CET (GLOBE NEWSWIRE) -- Copenhagen, 7 December 2015 – Pursuant to the Danish Securities Trading Act, section 28a, Zealand disclose information on transactions with the company’s shares and related securities by executives and persons/companies closely related to them. With reference to the above, Zealand announces it has received information on the below transactions for disclosure. Name: Helle Størum ---------------------------------------------------------------- Reason: Employee elected member of the Board of Directors ---------------------------------------------------------------- Issuer: Zealand Pharma A/S ---------------------------------------------------------------- Designation: Shares ---------------------------------------------------------------- ISIN Code: DK0060257814 ---------------------------------------------------------------- Transaction: Sale of shares ---------------------------------------------------------------- Trading Date: 3 December 2015 ---------------------------------------------------------------- Market: Nasdaq Copenhagen ---------------------------------------------------------------- Number: 2,000 ---------------------------------------------------------------- Price: DKK 149.00 ---------------------------------------------------------------- Total value: DKK 298,000.00 ---------------------------------------------------------------- ????? For further information, please contact: Hanne Leth Hillman, Senior Vice President, Investor Relations and Communications Tel: +45 50 60 36 89, email: hlh@zealandpharma.com About Zealand Pharma Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim. Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® by Sanofi and under regulatory review in the US. The license agreement with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus®) which is on track for regulatory submission in the US in December 2015 and in the European Union in Q1 2016. The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics. The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma